132 related articles for article (PubMed ID: 34645318)
21. Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Future Oncol; 2019 Mar; 15(9):1021-1034. PubMed ID: 30757910
[TBL] [Abstract][Full Text] [Related]
22. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
23. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
[TBL] [Abstract][Full Text] [Related]
24. Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Future Oncol; 2024 Mar; ():1-11. PubMed ID: 38547003
[TBL] [Abstract][Full Text] [Related]
25. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
Meyers J; Yu Y; Kaye JA; Davis KL
Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
[TBL] [Abstract][Full Text] [Related]
26. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
Cai Q; Chen Y; Zou D; Zhang L; Badillo M; Zhou S; Lopez E; Jiang W; Huang H; Lin T; Romaguera J; Wang M
Oncotarget; 2014 Sep; 5(17):7368-80. PubMed ID: 25228589
[TBL] [Abstract][Full Text] [Related]
28. Clinical approach to diffuse large B cell lymphoma.
Caimi PF; Hill BT; Hsi ED; Smith MR
Blood Rev; 2016 Nov; 30(6):477-491. PubMed ID: 27596109
[TBL] [Abstract][Full Text] [Related]
29. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
30. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
[TBL] [Abstract][Full Text] [Related]
31. Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma.
Tsutsué S; Makita S; Yi J; Crawford B
Future Oncol; 2021 Nov; 17(33):4511-4525. PubMed ID: 34414783
[No Abstract] [Full Text] [Related]
32. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B Cell Lymphoma Treated with Second-Line Therapy and Intent to Transplant.
Vardhana S; Hamlin PA; Yang J; Zelenetz A; Sauter CS; Matasar MJ; Ni A; Yahalom J; Moskowitz CH
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2133-2138. PubMed ID: 29909154
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study.
Kim JW; Kim SW; Tada K; Fukuda T; Lee JH; Lee JJ; Kwon JH; Bang SM; Kim I; Yoon SS; Lee JS; Park S
Ann Hematol; 2014 Aug; 93(8):1345-51. PubMed ID: 24633661
[TBL] [Abstract][Full Text] [Related]
36. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
37. Temporal trends in treatment and survival of older adult diffuse large B-Cell lymphoma patients in the SEER-Medicare linked database.
Shaw J; Harvey C; Richards C; Kim C
Leuk Lymphoma; 2019 Dec; 60(13):3235-3243. PubMed ID: 31185769
[TBL] [Abstract][Full Text] [Related]
38. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls.
Hill BT; Rybicki L; Bolwell BJ; Smith S; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E; Sweetenham J
Br J Haematol; 2011 Mar; 152(5):561-9. PubMed ID: 21223255
[TBL] [Abstract][Full Text] [Related]
39. Updated Results of Rituximab Pre- and Post-BEAM with or without
Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
[No Abstract] [Full Text] [Related]
40. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
